New shot could tame hay fever misery
NCT ID NCT07091357
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tests an injection called SHR-1819 in 100 adults with seasonal allergic rhinitis (hay fever). Participants will receive either the drug or a placebo to see if it reduces daily nasal symptoms like sneezing and stuffiness. The trial is double-blind, meaning neither patients nor doctors know who gets the real drug.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SHR-1819 injection
- What this could lead to
- If it works, this could offer a new treatment option to reduce nasal allergy symptoms during pollen seasons.
- What could go wrong
- This is an early Phase 2 trial with only 100 participants, so results may not apply to everyone. The drug may not work better than a placebo or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEASONAL ALLERGIC RHINITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Tongren Hospital, Capital Medical University
RECRUITINGBeijing, Beijing Municipality, 100730, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pinpoint pollen dose unmask allergy triggers?
- New allergy pill could offer relief from sneezing and stuffy nose
- New injection could tame seasonal allergy symptoms for those failed by standard treatments
- New shot for teen hay fever? early trial underway
- Nasal spray test could make allergy shots smarter and cheaper
- New allergy drug AK139 aims to stop sneezing and stuffy noses